260 related articles for article (PubMed ID: 30463611)
1. Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
Houvenaeghel G; Cohen M; Raro P; De Troyer J; de Lara CT; Gimbergues P; Gauthier T; Faure-Virelizier C; Vaini-Cowen V; Lantheaume S; Regis C; Darai E; Ceccato V; D'Halluin G; Del Piano F; Villet R; Jouve E; Beedassy B; Theret P; Gabelle P; Zinzindohoue C; Opinel P; Marsollier-Ferrer C; Dhainaut-Speyer C; Colombo PE; Lambaudie E; Tallet A; Boher JM;
BMC Cancer; 2018 Nov; 18(1):1153. PubMed ID: 30463611
[TBL] [Abstract][Full Text] [Related]
2. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
3. Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial.
Houvenaeghel G; Cohen M; Raro P; De Troyer J; Gimbergues P; Tunon de Lara C; Ceccato V; Vaini-Cowen V; Faure-Virelizier C; Marchal F; Gauthier T; Jouve E; Theret P; Regis C; Gabelle P; Pernaut J; Del Piano F; D'Halluin G; Lantheaume S; Darai E; Beedassy B; Dhainaut-Speyer C; Martin X; Girard S; Villet R; Monrigal E; Hoyek T; Le Brun JF; Colombo PE; Tallet A; Boher JM;
NPJ Breast Cancer; 2021 Oct; 7(1):133. PubMed ID: 34625562
[TBL] [Abstract][Full Text] [Related]
4. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
5. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
6. [Sentinel node invasion: is it necessary to perform axillary lymph node dissection? Randomized trial SERC].
Houvenaeghel G; Resbeut M; Boher JM
Bull Cancer; 2014 Apr; 101(4):358-63. PubMed ID: 24793627
[TBL] [Abstract][Full Text] [Related]
7. Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?
Sávolt A; Polgár C; Musonda P; Mátrai Z; Rényi-Vámos F; Tóth L; Kásler M; Péley G
Clin Breast Cancer; 2013 Oct; 13(5):364-70. PubMed ID: 23773380
[TBL] [Abstract][Full Text] [Related]
8. The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases.
Houvenaeghel G; de Nonneville A; Chopin N; Classe JM; Mazouni C; Chauvet MP; Reyal F; Tunon de Lara C; Jouve E; Rouzier R; Daraï E; Gimbergues P; Coutant C; Azuar AS; Villet R; Crochet P; Rua S; Bannier M; Cohen M; Boher JM
Cancer Med; 2023 Feb; 12(4):4023-4032. PubMed ID: 36127853
[TBL] [Abstract][Full Text] [Related]
9. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
Riedel F; Heil J; Feißt M; Rezai M; Moderow M; Sohn C; Schütz F; Golatta M; Hennigs A
Breast Cancer Res Treat; 2019 Sep; 177(2):457-467. PubMed ID: 31236814
[TBL] [Abstract][Full Text] [Related]
10. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
Tvedskov TF
Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
[TBL] [Abstract][Full Text] [Related]
11. Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer.
Malter W; Hellmich M; Badian M; Kirn V; Mallmann P; Krämer S
Anticancer Res; 2018 Jun; 38(6):3657-3662. PubMed ID: 29848724
[TBL] [Abstract][Full Text] [Related]
12. Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases.
Majid S; Rydén L; Manjer J
BMC Cancer; 2019 Jun; 19(1):626. PubMed ID: 31238899
[TBL] [Abstract][Full Text] [Related]
13. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
Poodt IGM; Spronk PER; Vugts G; van Dalen T; Peeters MTFDV; Rots ML; Kuijer A; Nieuwenhuijzen GAP; Schipper RJ
Ann Surg; 2018 Dec; 268(6):1084-1090. PubMed ID: 28742702
[TBL] [Abstract][Full Text] [Related]
14. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
Verheuvel NC; Voogd AC; Tjan-Heijnen VC; Roumen RM
Eur J Surg Oncol; 2016 Aug; 42(8):1162-8. PubMed ID: 27265036
[TBL] [Abstract][Full Text] [Related]
15. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
[TBL] [Abstract][Full Text] [Related]
16. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
[TBL] [Abstract][Full Text] [Related]
17. The administration of adjuvant chemo(-immuno) therapy in the post ACOSOG-Z0011 era; a population based study.
Poodt IGM; Rots ML; Vugts G; van Dalen T; Kuijer A; Vriens BEPJ; Nieuwenhuijzen GAP; Schipper RJ
Eur J Surg Oncol; 2018 Aug; 44(8):1151-1156. PubMed ID: 29580733
[TBL] [Abstract][Full Text] [Related]
18. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes.
Houvenaeghel G; Boher JM; Reyal F; Cohen M; Garbay JR; Classe JM; Rouzier R; Giard S; Faure C; Charitansky H; Tunon de Lara C; Daraï E; Hudry D; Azuar P; Gimbergues P; Villet R; Sfumato P; Lambaudie E
Eur J Cancer; 2016 Nov; 67():106-118. PubMed ID: 27640137
[TBL] [Abstract][Full Text] [Related]
19. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
Riedel F; Heil J; Feisst M; Moderow M; von Au A; Domschke C; Michel L; Schaefgen B; Golatta M; Hennigs A
Breast Cancer Res Treat; 2020 Nov; 184(2):627-636. PubMed ID: 32816190
[TBL] [Abstract][Full Text] [Related]
20. Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study.
Gannan E; Khoo J; Nightingale S; Suhardja TS; Lippey J; Keane H; Tan KJ; Clouston D; Gorelik A; Mann GB;
Breast J; 2016 Jul; 22(4):413-9. PubMed ID: 27095381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
